Previous 10 | Next 10 |
Relay Therapeutics Inc. (RLAY) is expected to report $-0.83 for Q3 2023
2023-11-03 01:07:35 ET More on Relay Therapeutics Relay Therapeutics surges 13% on early-stage data on tumors asset Seeking Alpha’s Quant Rating on Relay Therapeutics For further details see: Relay Therapeutics GAAP EPS of -$0.54, revenue of $25.2M
Reported initial RLY-4008 (lirafugratinib) data demonstrating durable responses across multiple FGFR2-altered solid tumors Announced plans to initiate RLY-2608 + fulvestrant + CDK4/6 triplet combinations in HR+/HER2- breast cancer by YE 2023 Updated pipeline to extend cash runwa...
CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2023 financial resu...
2023-10-13 15:00:54 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
2023-10-12 19:15:54 ET More on Relay Therapeutics Relay Therapeutics: Market May Be Prematurely Dismissing RLY-2608 Seeking Alpha’s Quant Rating on Relay Therapeutics Historical earnings data for Relay Therapeutics Financial information for Relay Thera...
2023-10-12 17:48:17 ET Gainers: Comtech Telecommunications ( CMTL ) +14% . Relay Therapeutics ( RLAY ) +12% . Ovid Therapeutics ( OVID ) +6% . Groupon ( GRPN ) +5% . Omeros Corporation ( OMER ) +4% . Losers: O...
35% ORR in patients with FGFR2 fusions (excluding CCA) & 40% ORR in patients with FGFR2-altered HR+/HER2- breast cancer RLY-4008 commercialization plans to focus on broader tumor agnostic opportunities Clinical focus on PI3Kα mutant selective programs, with plans to i...
CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that data for RLY-4008 (lira...
2023-08-08 16:32:54 ET Relay Therapeutics press release ( NASDAQ: RLAY ): Q2 GAAP EPS of -$0.81 beats by $0.01 . Revenue of $0.12M (-67.6% Y/Y) misses by $0.59M . For further details see: Relay Therapeutics GAAP EPS of -$0.81 beats by $0.01, revenue of $0...
News, Short Squeeze, Breakout and More Instantly...
Relay Therapeutics Inc. Company Name:
RLAY Stock Symbol:
NASDAQ Market:
Relay Therapeutics Inc. Website:
2024-06-14 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
3 new programs include 2 genetic disease programs – vascular malformations & Fabry disease – & 1 precision oncology program – NRAS-specific inhibitor Cash guidance remains unchanged, and is expected to fund operations into second half of 2026 Relay T...
CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced a clinical trial collabor...